FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027869711> ?p ?o ?g. }

• W2027869711 endingPage "412" @default.
• W2027869711 startingPage "400" @default.
• W2027869711 abstract "Relief of unilateral ureteral obstruction (UUO) of 24 h duration in rats is followed by severe renal vasoconstriction in the postobstructive kidney (POK). The present study examined possible roles of renal prostaglandins (PG) and thromboxanes (TX), as well as the renin-angiotensin system, in this vasoconstriction. Administration of the cyclooxygenase inhibitor indomethacin, which blocks both PG and TX production, failed to improve POK hemodynamics in UUO rats. To explore the possible role of the TX compounds, which include the potent vasoconstrictor thromboxane A2 (TXA2), UUO rats were infused with imidazole, an agent that blocks synthesis of TX, but not of PG. Imidiazole led to two- to threefold increases in the clearance of both inulin and rho-aminohippuric acid by the POK. This effect of imidazole was abolished by indomethacin, suggesting that the amelioration of POK vasoconstriction by imidazole was a result of inhibition of vasoconstrictor TX synthesis (e.g. TXA2), with PG vasodilators (e.g. PGE2 or PG12) still active. Urea, infused in a solution whose osmolality and volume were identical to the imidazole infusion, failed to improve hemodynamics in the POK, making it unlikely that nonspecific effects of volume expansion or osmotic diuresis mediated the beneficial effect of imidazole. Further studies examined the possible role of the renin-angiotensin systems in the vasoconstriction of the POK. UUO rats infused with the angiotensin II antagonist, Saralasin, exhibited no significant improvement in POK function, a finding that might be at least partly attributable to agonist/vasoconstrictor properties of Saralasin. In other experiments, treatment of UUO rats with the angiotensin-converting enzyme blocker SQ 14225 (Captopril), in order to inhibit angiotensin II formation, led to at least twofold increases in the clearance of both inulin and rho-aminohippuric acid in the POK. It is unlikely that Captopril exerted this beneficial effect by potentiating the vasodilator kinins, because the effect was not diminished by administration of either carboxypeptidase B (which destroys the kinins) or Trasylol (which blocks kinin synthesis). Thus, these results suggest that both angiotensin II, as well as metabolites of the PG-TX system, may be important determinants of postobstructive renal hemodynamics in the rat." @default.
• W2027869711 created "2016-06-24" @default.
• W2027869711 creator A5004274775 @default.
• W2027869711 creator A5044715402 @default.
• W2027869711 creator A5071111737 @default.
• W2027869711 date "1980-02-01" @default.
• W2027869711 modified "2023-10-16" @default.
• W2027869711 title "Obstructive nephropathy in the rat: possible roles for the renin-angiotensin system, prostaglandins, and thromboxanes in postobstructive renal function." @default.
• W2027869711 cites W1952779275 @default.
• W2027869711 cites W1977482543 @default.
• W2027869711 cites W1979711727 @default.
• W2027869711 cites W1988439025 @default.
• W2027869711 cites W1988646839 @default.
• W2027869711 cites W1998629158 @default.
• W2027869711 cites W2000748410 @default.
• W2027869711 cites W2016036756 @default.
• W2027869711 cites W2019021276 @default.
• W2027869711 cites W2031587843 @default.
• W2027869711 cites W2040618263 @default.
• W2027869711 cites W2044055632 @default.
• W2027869711 cites W2052402552 @default.
• W2027869711 cites W2058994566 @default.
• W2027869711 cites W2073637084 @default.
• W2027869711 cites W2079656603 @default.
• W2027869711 cites W2267324674 @default.
• W2027869711 cites W2283280951 @default.
• W2027869711 cites W2413392260 @default.
• W2027869711 cites W2414175313 @default.
• W2027869711 cites W2414283352 @default.
• W2027869711 cites W2415409554 @default.
• W2027869711 cites W2417888268 @default.
• W2027869711 cites W2423384520 @default.
• W2027869711 cites W2438420855 @default.
• W2027869711 doi "https://doi.org/10.1172/jci109683" @default.
• W2027869711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/371378" @default.
• W2027869711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7356687" @default.
• W2027869711 hasPublicationYear "1980" @default.
• W2027869711 type Work @default.
• W2027869711 sameAs 2027869711 @default.
• W2027869711 citedByCount "209" @default.
• W2027869711 countsByYear W20278697112012 @default.
• W2027869711 countsByYear W20278697112013 @default.
• W2027869711 countsByYear W20278697112014 @default.
• W2027869711 countsByYear W20278697112015 @default.
• W2027869711 countsByYear W20278697112016 @default.
• W2027869711 countsByYear W20278697112017 @default.
• W2027869711 countsByYear W20278697112018 @default.
• W2027869711 countsByYear W20278697112019 @default.
• W2027869711 countsByYear W20278697112020 @default.
• W2027869711 countsByYear W20278697112022 @default.
• W2027869711 countsByYear W20278697112023 @default.
• W2027869711 crossrefType "journal-article" @default.
• W2027869711 hasAuthorship W2027869711A5004274775 @default.
• W2027869711 hasAuthorship W2027869711A5044715402 @default.
• W2027869711 hasAuthorship W2027869711A5071111737 @default.
• W2027869711 hasBestOaLocation W20278697111 @default.
• W2027869711 hasConcept C126322002 @default.
• W2027869711 hasConcept C134018914 @default.
• W2027869711 hasConcept C170493617 @default.
• W2027869711 hasConcept C174459258 @default.
• W2027869711 hasConcept C185592680 @default.
• W2027869711 hasConcept C198710026 @default.
• W2027869711 hasConcept C2776823063 @default.
• W2027869711 hasConcept C2779961880 @default.
• W2027869711 hasConcept C2780091579 @default.
• W2027869711 hasConcept C2781024287 @default.
• W2027869711 hasConcept C2908929049 @default.
• W2027869711 hasConcept C71924100 @default.
• W2027869711 hasConcept C84393581 @default.
• W2027869711 hasConcept C98274493 @default.
• W2027869711 hasConceptScore W2027869711C126322002 @default.
• W2027869711 hasConceptScore W2027869711C134018914 @default.
• W2027869711 hasConceptScore W2027869711C170493617 @default.
• W2027869711 hasConceptScore W2027869711C174459258 @default.
• W2027869711 hasConceptScore W2027869711C185592680 @default.
• W2027869711 hasConceptScore W2027869711C198710026 @default.
• W2027869711 hasConceptScore W2027869711C2776823063 @default.
• W2027869711 hasConceptScore W2027869711C2779961880 @default.
• W2027869711 hasConceptScore W2027869711C2780091579 @default.
• W2027869711 hasConceptScore W2027869711C2781024287 @default.
• W2027869711 hasConceptScore W2027869711C2908929049 @default.
• W2027869711 hasConceptScore W2027869711C71924100 @default.
• W2027869711 hasConceptScore W2027869711C84393581 @default.
• W2027869711 hasConceptScore W2027869711C98274493 @default.
• W2027869711 hasIssue "2" @default.
• W2027869711 hasLocation W20278697111 @default.
• W2027869711 hasLocation W20278697112 @default.
• W2027869711 hasLocation W20278697113 @default.
• W2027869711 hasLocation W20278697114 @default.
• W2027869711 hasOpenAccess W2027869711 @default.
• W2027869711 hasPrimaryLocation W20278697111 @default.
• W2027869711 hasRelatedWork W1989120855 @default.
• W2027869711 hasRelatedWork W2016647631 @default.
• W2027869711 hasRelatedWork W2042660006 @default.
• W2027869711 hasRelatedWork W2046293867 @default.
• W2027869711 hasRelatedWork W2069471327 @default.
• W2027869711 hasRelatedWork W2071078849 @default.
• W2027869711 hasRelatedWork W2076377378 @default.

• next